Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,316
  • Shares Outstanding, K 99,474
  • Annual Sales, $ 147,750 K
  • Annual Income, $ -284,230 K
  • 60-Month Beta 0.88
  • Price/Sales 0.86
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FGEN with:

Options Overview Details

View History
  • Implied Volatility 243.54% ( +65.51%)
  • Historical Volatility 95.37%
  • IV Percentile 79%
  • IV Rank 20.97%
  • IV High 1,142.70% on 01/22/24
  • IV Low 4.94% on 08/31/23
  • Put/Call Vol Ratio 5.27
  • Today's Volume 614
  • Volume Avg (30-Day) 2,123
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 50,108
  • Open Int (30-Day) 45,841

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.27
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9011 +44.27%
on 04/25/24
1.7400 -25.29%
on 05/07/24
+0.3157 (+32.07%)
since 04/24/24
3-Month
0.9011 +44.27%
on 04/25/24
2.8000 -53.57%
on 03/25/24
-0.5200 (-28.57%)
since 02/23/24
52-Week
0.3333 +290.04%
on 11/10/23
19.4700 -93.32%
on 06/05/23
-15.6800 (-92.34%)
since 05/24/23

Most Recent Stories

More News
FibroGen: Q1 Earnings Snapshot

FibroGen: Q1 Earnings Snapshot

FGEN : 1.3000 (+1.56%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 1.3000 (+1.56%)
FibroGen: Q3 Earnings Snapshot

FibroGen: Q3 Earnings Snapshot

FGEN : 1.3000 (+1.56%)
Stocks Move Higher Before the Open as Investors Await Key U.S. GDP Data, Salesforce Earnings on Tap

September S&P 500 futures (ESU23) are up +0.06%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.07% this morning after three major U.S. benchmark indices rallied on Tuesday as soft economic...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
CTLT : 54.82 (+0.31%)
PDD : 157.57 (+2.56%)
VZ : 39.74 (+0.79%)
T : 17.50 (+0.17%)
CRM : 272.29 (-2.25%)
CRWD : 351.47 (+2.66%)
CHWY : 16.57 (+1.91%)
ORSTE.C.DX : 401.800 (-0.57%)
PRU.LN : 765.800 (-0.39%)
HPQ : 32.75 (+0.31%)
FibroGen: Q2 Earnings Snapshot

FibroGen: Q2 Earnings Snapshot

FGEN : 1.3000 (+1.56%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are...

FGEN : 1.3000 (+1.56%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are...

FGEN : 1.3000 (+1.56%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are...

FGEN : 1.3000 (+1.56%)
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?

Its pipeline is looking thin, and it might hit another speed bump quite soon.

FGEN : 1.3000 (+1.56%)
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -6.58% and 17.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 1.3000 (+1.56%)
CTIC : 9.09 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 1.4533
2nd Resistance Point 1.4067
1st Resistance Point 1.3533
Last Price 1.3000
1st Support Level 1.2533
2nd Support Level 1.2067
3rd Support Level 1.1533

See More

52-Week High 19.4700
Fibonacci 61.8% 12.1598
Fibonacci 50% 9.9016
Fibonacci 38.2% 7.6435
Last Price 1.3000
52-Week Low 0.3333

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar